Company Filing History:
Years Active: 2013
Title: Innovations of Thierry Bussiere in Alzheimer's Research
Introduction
Thierry Bussiere is an accomplished inventor based in Cambridge, MA, specializing in neuroactive fragments of human amyloid precursor protein (APP). His work focuses on developing innovative solutions for Alzheimer's and other amyloidogenic diseases. With a patent to his name, Bussiere is making significant contributions to the field of neurobiology.
Latest Patents
Bussiere holds a patent for "Neuroactive fragments of APP." This application provides novel neuroactive fragments that include sequences from the Aβ region of APP, extending upstream. The fragments are soluble in aqueous solutions, with most bands being about 10 kDa and above, which do not correspond with the expected molecular weight of a dimer or trimer. These fragments can be utilized as immunogens in immunotherapy methods aimed at treating Alzheimer's disease and other conditions characterized by Aβ deposits in the brain. Additionally, antibodies targeting the fragment upstream from APP or the interface between Aβ and the upstream sequence can be employed in therapeutic methods. The fragments also serve as useful markers for diagnosing or prognosing diseases and for screening agents.
Career Highlights
Bussiere is currently associated with Janssen Alzheimer Immunotherapy, where he continues to advance research in Alzheimer's treatment. His innovative approach to neuroactive fragments has positioned him as a key figure in the fight against neurodegenerative diseases.
Collaborations
Bussiere collaborates with notable colleagues, including Kelly Johnson-Wood and Peter Andrew Seubert, who contribute to the research and development of therapeutic strategies in Alzheimer's disease.
Conclusion
Thierry Bussiere's work in developing neuroactive fragments of APP represents a significant advancement in Alzheimer's research. His contributions are paving the way for innovative therapeutic approaches to combat this challenging disease.